Processa Pharmaceuticals Inc Stock News

Processa Pharmaceuticals said on Wednesday it acquired privately held Vidya Therapeutics in an all-stock ​deal, gaining access to its lead candidate ‌being developed to target diseases involving the immune system.

Acquisition brings into Processa's pipeline Vidya's lead asset, VT-7208, a next-generation, CNS-penetrant, once-daily, oral potentially best-in-class Bruton's tyrosine kinase inhibitor (BTKi) designed to overcome the efficacy and safety limitations of early-generation BTKi programs Concurrent oversubscribed private placement financing of approximately $200 million committed by a syndicate of le...